High variability in assays of blood markers of collagen turnover in cardiovascular disease: Implications for research and clinical practice

Rubiś, P. P., Dziewięcka, E., González, A. and Cleland, J. G.F. (2024) High variability in assays of blood markers of collagen turnover in cardiovascular disease: Implications for research and clinical practice. European Journal of Heart Failure, (doi: 10.1002/ejhf.3375) (PMID:38980205) (Early Online Publication)

[img] Text
330315.pdf - Accepted Version
Restricted to Repository staff only until 9 July 2025.

514kB

Abstract

Aims: Fibrosis is a common feature of many chronic diseases, including heart failure, which can have deleterious effects on cardiac structure and function that are associated with adverse outcomes. By-products of collagen synthesis and degradation, such as carboxy- and amino-terminal pro- or telo-peptides of collagen type I and III (PICP, PINP, PIIINP, and CITP) have been extensively investigated as markers of fibrosis. Although the majority of studies report on the reproducibility of their assay results, there is no a comparison of biomarker assays across studies. Therefore, we conducted a systematic review adhering to PRISMA guidelines. Methods and results: The search terms employed in Medline were: ‘collagen AND cardiac’ or ‘collagen AND heart’. This query yielded a total of 1049 articles. Thereafter, specific search criteria were applied: (i) original English-language papers; (ii) human studies; (iii) in-vivo investigations; and (iv) blood/serum/plasma samples. Overall, 89 studies were identified (42 on PIIINP, 32 on PICP, 29 on CITP, and 17 on PINP). The range of reported values for PIIINP was between 0.06 to 11 800 μg/l; for PICP 0.006 to 1265 μg/l; for CITP 0.3 to 5450 μg/l; for PINP 0.15 to 80 μg/l. Extreme variations in values for fibrosis biomarkers were observed across studies, especially when different assays were used, but also with the same assays. Conclusions: Our findings show that it is challenging to ascertain normal ranges or compare studies for the measurement of fibrosis biomarkers. Given the potential implications for clinical practice and current lack of awareness of these issues, this subject warrants comprehensive acknowledgement and understanding.

Item Type:Articles
Additional Information:This work was funded through the National Science Centre, Poland (grant number 2018/29/B/NZ5/02588) and Instituto de Salud CarlosIII: CIBERCV CB16/11/00483 and PI21/00946 co-financed by ERDFfunds.
Keywords:Assay, fibrosis, collagen, variability, biomarker.
Status:Early Online Publication
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Rubiś, P. P., Dziewięcka, E., González, A., and Cleland, J. G.F.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:European Journal of Heart Failure
Publisher:Wiley
ISSN:1388-9842
ISSN (Online):1879-0844
Published Online:09 July 2024
Copyright Holders:Copyright © 2024 European Society of Cardiology
First Published:First published in European Journal of Heart Failure 2024
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record